BR112016030111A2 - solid composite formulation for oral administration, and method of preparing the solid composite formulation for oral administration - Google Patents

solid composite formulation for oral administration, and method of preparing the solid composite formulation for oral administration

Info

Publication number
BR112016030111A2
BR112016030111A2 BR112016030111A BR112016030111A BR112016030111A2 BR 112016030111 A2 BR112016030111 A2 BR 112016030111A2 BR 112016030111 A BR112016030111 A BR 112016030111A BR 112016030111 A BR112016030111 A BR 112016030111A BR 112016030111 A2 BR112016030111 A2 BR 112016030111A2
Authority
BR
Brazil
Prior art keywords
oral administration
solid composite
composite formulation
preparing
ezetimibe
Prior art date
Application number
BR112016030111A
Other languages
Portuguese (pt)
Inventor
Young Jeong Ha
Hyun Park Jae
Soo Woo Jong
Soo Kim Kyeong
Jun Lee Seung
Il Kim Yong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016030111(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112016030111A2 publication Critical patent/BR112016030111A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção proporciona uma formulação compósita sólida para administração oral que inclui: uma porção de grânulos úmidos de ezetimiba incluindo ezetimiba que é granulada a úmido usando um granulador de leito fluidizado; e uma porção de mistura de rosuvastatina incluindo rosuvastatina ou um seu sal farmaceuticamente aceitável.The present invention provides a solid composite formulation for oral administration comprising: a portion of ezetimibe wet granules including ezetimibe that is wet granulated using a fluidized bed granulator; and a rosuvastatin mixture portion including rosuvastatin or a pharmaceutically acceptable salt thereof.

BR112016030111A 2014-06-25 2015-06-09 solid composite formulation for oral administration, and method of preparing the solid composite formulation for oral administration BR112016030111A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140078388A KR101977785B1 (en) 2014-06-25 2014-06-25 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
PCT/KR2015/005779 WO2015199356A1 (en) 2014-06-25 2015-06-09 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
BR112016030111A2 true BR112016030111A2 (en) 2017-08-22

Family

ID=54938391

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030111A BR112016030111A2 (en) 2014-06-25 2015-06-09 solid composite formulation for oral administration, and method of preparing the solid composite formulation for oral administration

Country Status (10)

Country Link
KR (1) KR101977785B1 (en)
AR (1) AR100977A1 (en)
BR (1) BR112016030111A2 (en)
CL (1) CL2016003283A1 (en)
EC (1) ECSP16096477A (en)
JO (1) JOP20150154B1 (en)
SG (2) SG11201610748RA (en)
TW (1) TWI700100B (en)
UY (1) UY36190A (en)
WO (1) WO2015199356A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2016539A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active substances and a method of its preparation
CZ2016538A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active ingredients
KR102206535B1 (en) * 2016-11-29 2021-01-22 한미약품 주식회사 Oral composite tablet comprising ezetimibe and rosuvastatin
EP3437636A1 (en) * 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
KR102500643B1 (en) * 2019-04-18 2023-02-16 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and losartan
KR20200137243A (en) 2019-05-29 2020-12-09 콜마파마(주) Process for preparation of pharmaceutical combination containing ezetimibe and rosuvastatin
BR112022001783A2 (en) 2019-07-31 2022-03-22 Tecnimede Soc Tecnico Medicinal Sa Immediate release multi-unit solid oral compositions, their methods and uses.
WO2022045759A1 (en) * 2020-08-25 2022-03-03 주식회사 대웅제약 Pharmaceutical composition in single dosage form for treating or preventing hypertension and hypercholesterolemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100907144B1 (en) * 2007-09-05 2009-07-09 박재섭 The golf club using moving ball
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011012912A2 (en) * 2009-07-28 2011-02-03 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság New granulating process and thus prepared granulate
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
PT2844233T (en) * 2012-05-01 2020-06-25 Althera Life Sciences Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases

Also Published As

Publication number Publication date
UY36190A (en) 2015-10-30
SG10201811586YA (en) 2019-02-27
AR100977A1 (en) 2016-11-16
TW201625223A (en) 2016-07-16
KR101977785B1 (en) 2019-05-14
TWI700100B (en) 2020-08-01
KR20160000762A (en) 2016-01-05
SG11201610748RA (en) 2017-01-27
CL2016003283A1 (en) 2017-07-28
JOP20150154B1 (en) 2021-08-17
WO2015199356A1 (en) 2015-12-30
ECSP16096477A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
BR112016030111A2 (en) solid composite formulation for oral administration, and method of preparing the solid composite formulation for oral administration
GT201600137A (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBE AND ROSUVASTATIN
CU20160185A7 (en) HETEROARILO COMPOUNDS FOR INHIBITION OF CINASA
CR20180253A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN UNMUNODEFICIENCY VIRUS
BR112017028140A2 (en) pharmaceutical formulations
BR112017008993A2 (en) Methods and Compositions Specifically for the Treatment of Attention Deficit Disorder
MX2017005484A (en) Dopamine d3 receptor antagonists compounds.
BR112017010423A2 (en) sublingual formulation of riluzole
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2016014696A (en) Combinations of formoterol and budesonide for the treatment of copd.
IL262204A (en) Granule formulation for oral administration
BR112017022846A2 (en) tamper-proof fixed dose combination that provides rapid release of two different particle drugs
MX2016014859A (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases.
BR112017001695A2 (en) combination therapy
BR112018071363A2 (en) oral nicotinamide pharmaceutical compositions
EA201692479A1 (en) PHARMACEUTICAL COMPOSITION, WHICH CONTAINS THE CONNECTION OF PYRAZINKARBOXAMIDE AS AN ACTIVE INGREDIENT
AR099943A1 (en) CHRICAL DERIVATIVES OF 2,5-DISPOSED CYCLOPENTANCARBOXYL ACID AND ITS USE
BR112017022856A2 (en) tamper-proof fixed dose combination that provides rapid release of two drugs from particles
BR112016015175A2 (en) PHARMACEUTICAL FORMULATION, METHOD FOR MANUFACTURING A PHARMACEUTICAL FORMULATION COMPRISING SILDENAFIL AND CLOMIPRAMINE AND TABLET
BR112017022335A2 (en) tamper evident fixed dose combination that provides rapid release of two drugs from particles and matrix
PH12016502540A1 (en) Pharmaceutical dosage forms
BR112017022855A2 (en) tamper-proof fixed dose combination providing rapid release of two drugs from particles and one powder
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]